dichloromethotrexate + fluorodeoxyuridine + mitomycin c

This is a combination chemotherapy regimen consisting of three antineoplastic agents: - **Dichloromethotrexate** is a chlorinated derivative of methotrexate, an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, thereby blocking DNA synthesis and cell replication. - **Fluorodeoxyuridine (FUDR)** is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. - **Mitomycin C** is an alkylating agent that crosslinks DNA, leading to inhibition of DNA synthesis and function. The combination targets rapidly dividing cancer cells through multiple mechanisms affecting nucleotide metabolism and direct DNA damage. Such regimens are typically used in oncology for synergistic cytotoxic effects against various solid tumors or hematologic malignancies. The specific indications for this exact triple-drug combination are not well-documented in standard references; however, each component has established use in cancer therapy as part of multi-agent protocols.

Other names

dichloromethotrexate + fluorodeoxyuridine + mitomycin c